Royal Bank of Canada’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59K | Buy |
2,917
+1,686
| +137% | +$27.2K | ﹤0.01% | 5402 |
|
|
2025
Q4 | $20K | Sell |
1,231
-20,141
| -94% | -$267K | ﹤0.01% | 6045 |
|
|
2025
Q3 | $260K | Sell |
21,372
-42,922
| -67% | -$593K | ﹤0.01% | 4919 |
|
|
2025
Q2 | $727K | Buy |
64,294
+64,143
| +42,479% | +$784K | ﹤0.01% | 4181 |
|
|
2025
Q1 | $2K | Sell |
151
-548
| -78% | -$5.59K | ﹤0.01% | 6571 |
|
|
2024
Q4 | $6K | Sell |
699
-3,294
| -82% | -$34.1K | ﹤0.01% | 6495 |
|
|
2024
Q3 | $47K | Buy |
3,993
+411
| +11% | +$5.17K | ﹤0.01% | 5726 |
|
|
2024
Q2 | $42K | Buy |
3,582
+2,880
| +410% | +$33.6K | ﹤0.01% | 5733 |
|
|
2024
Q1 | $8K | Sell |
702
-9,088
| -93% | -$121K | ﹤0.01% | 6282 |
|
|
2023
Q4 | $120K | Buy |
9,790
+5,564
| +132% | +$50.6K | ﹤0.01% | 5500 |
|
|
2023
Q3 | $41K | Sell |
4,226
-266
| -6% | -$2.72K | ﹤0.01% | 5881 |
|
|
2023
Q2 | $40K | Buy |
4,492
+3,113
| +226% | +$28.7K | ﹤0.01% | 5880 |
|
|
2023
Q1 | $11K | Sell |
1,379
-2,953
| -68% | -$22K | ﹤0.01% | 6265 |
|
|
2022
Q4 | $29K | Sell |
4,332
-5,515
| -56% | -$29.5K | ﹤0.01% | 6149 |
|
|
2022
Q3 | $143K | Buy |
9,847
+9,709
| +7,036% | +$136K | ﹤0.01% | 5046 |
|
|
2022
Q2 | $1K | Sell |
138
-1,238
| -90% | -$13.7K | ﹤0.01% | 7142 |
|
|
2022
Q1 | $20K | Sell |
1,376
-3,595
| -72% | -$51.7K | ﹤0.01% | 6605 |
|
|
2021
Q4 | $66K | Buy |
4,971
+2,646
| +114% | +$42.1K | ﹤0.01% | 6212 |
|
|
2021
Q3 | $41K | Sell |
2,325
-575
| -20% | -$11.7K | ﹤0.01% | 6275 |
|
|
2021
Q2 | $70K | Buy |
2,900
+1,112
| +62% | +$29.1K | ﹤0.01% | 5812 |
|
|
2021
Q1 | $46K | Buy |
1,788
+1,118
| +167% | +$29.4K | ﹤0.01% | 5933 |
|
|
2020
Q4 | $13K | Buy |
670
+649
| +3,090% | +$11.1K | ﹤0.01% | 6262 |
|
|
2020
Q3 | $0 | Buy |
+21
| New | +$263 | ﹤0.01% | 6781 |
|
|
2020
Q2 | – | Sell |
-32
| Closed | – | – | 6759 |
|
|
2020
Q1 | $0 | Sell |
32
-1,231
| -97% | -$16.6K | ﹤0.01% | 6850 |
|
|
2019
Q4 | $22K | Buy |
+1,263
| New | +$16.5K | ﹤0.01% | 5816 |
|
|
2018
Q4 | – | Sell |
-10
| Closed | – | – | 6930 |
|
|
2018
Q3 | $0 | Buy |
+10
| New | +$135 | ﹤0.01% | 6821 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | – | – | 6662 |
|
|
2017
Q1 | $0 | Buy |
+1
| New | +$8 | ﹤0.01% | 6716 |
|
|
2016
Q1 | – | Sell |
-357
| Closed | -$18K | – | 6509 |
|
|
2015
Q4 | $18K | Buy |
357
+317
| +793% | +$16.6K | ﹤0.01% | 5750 |
|
|
2015
Q3 | $2K | Sell |
40
-19
| -32% | -$1.62K | ﹤0.01% | 6376 |
|
|
2015
Q2 | $6K | Buy |
+59
| New | +$5.85K | ﹤0.01% | 6204 |
|
Other funds holding KALV
VA
FLSM
SCM
TCM
SCM
Royal Bank of Canada's KALV Position: Q1 2026 in Review
Royal Bank of Canada increased its KalVista Pharmaceuticals (KALV) stake by 137% in Q1 2026, buying an estimated $27.2K and bringing the position to 2,917 shares worth $59K. The position accounts for ﹤0.01% of the portfolio, ranked #5402.
Royal Bank of Canada first reported a position in KALV in Q2 2015 and has held it in 30 quarters since. The position peaked at $727K in Q2 2025. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.
- Royal Bank of Canada held 2,917 shares of KalVista Pharmaceuticals worth $59K as of Q1 2026.
- Royal Bank of Canada bought 1,686 KalVista Pharmaceuticals shares in Q1 2026, an estimated $27.2K.
- KalVista Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5402 holding.
- Royal Bank of Canada first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 30 quarters since.
- Royal Bank of Canada's KalVista Pharmaceuticals position peaked at $727K in Q2 2025.
- 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.